Skip to main content
S&P 5007,650.50+0.17%DOW51,682.64-0.18%NASDAQ26,522.54+0.39%BTC$81,273.00+6.27%ETH$2,618.91+7.14%GOLD$4,415.90+0.37%OIL$95.47-1.81%
Smart Investors Daily
HK

OTC · HKMPY

Hikma Pharmaceuticals PLC

Healthcare · Drug Manufacturers - Specialty & Generic

$41.31

Up+$0.00 (+0.00%)

Updated Sep 19, 2026, 3:30 AM

SID Score

5.9/10

Composite research score

Smart Money

46/100

Neutral

Market cap
4.58B
P/E ratio
12.27
Dividend yield
4.07%
52-week range
— – —
Volume
300
Avg. volume
4.42K

Price performance

HKMPY price history

1M range · 0 trading sessions · Daily adjusted prices

HKMPY does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest HKMPY news

The latest Smart Investors Daily articles mentioning HKMPY.

Stock researchCompany · Overview

HKMPY research

Overview

Company profile and research snapshot.

Company profile

HIKMA PHARMS PLC S/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
HKMPY recent ratings
DateFirmRatingTarget
Jul 16, 2026CitigroupBuy—
Jun 22, 2026DeutscheBuy—
May 5, 2026JefferiesBuy—
Apr 28, 2026Berenberg BankBuy—
Mar 4, 2026Berenberg BankBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 10, 2026

Hikma advances its epinephrine nasal spray with multi-market regulatory filings

Hikma Pharmaceuticals PLC (Hikma, Group) announces that regulatory submissions for its epinephrine nasal spray, being developed for the emergency treatment of allergic reactions (anaphylaxis), have been accepted for review by regulators in the United States, Europe, and the UK. Hikma has also filed a submission for its epinephrine nasal spray in Canada, with plans to expand filings beyond these markets in due course.

Yahoo · Sep 5, 2026

Hikma Pharmaceuticals (LSE:HIK) Stock Fair Value Edges Higher After Bullish Analyst Targets

Price targets for Hikma Pharmaceuticals are currently clustered in the £1,870 to £2,100 range, which sits above the latest fair value estimate of £19.70. Analysts linking these higher targets to Hikma Pharmaceuticals point to confidence in execution and valuation, although they also flag sensitivity to assumptions that could work against the stock if conditions change. As you read on, you will see how to interpret this evolving narrative and what to watch as new research comes...

Yahoo · Aug 25, 2026

Jefferies lifts Hikma target as CMO deal underpins growth story

Jefferies has raised its price target on Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) to 2,025p from 1,870p, pointing to the expanding contract manufacturing business as the source of the upgrade. The 'buy' rating is unchanged, with the new target implying 24% upside from Tuesday's share...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By